Treatment of bone-related cancers using placental stem cells

Abstract

Provided herein are methods of suppression of proliferation and growth of cells of bone-related cancers, e.g., multiple myeloma or chondrosarcoma cells, using placental cells, e.g., the placental stem cells described herein, and populations of such placental cells. Also provided herein are methods of treating individuals having cells of a bone-related cancer.

What is claimed: 
     
         1 . A method of suppressing the proliferation of cells of a bone-related cancer, comprising contacting said cells of a bone-related cancer with a plurality of placental stem cells for a time sufficient for said placental stem cells to suppress proliferation of said cells of a bone-related cancer, as compared to a plurality of said cells of a bone-related cancer not contacted with placental stem cells,
 wherein said placental stem cells are adherent to tissue culture plastic, are CD34 − , CD10 + , CD105 +  and CD200 +  as detectable by flow cytometry, and are not trophoblasts, cytotrophoblasts or bone marrow-derived mesenchymal stem cells.   
     
     
         2 . The method of  claim 1 , wherein said cells of a bone-related cancer are multiple myeloma cells. 
     
     
         3 . The method of  claim 1 , wherein said cells of a bone-related cancer are chondrosarcoma cells. 
     
     
         4 . The method of  claim 1 , wherein said cells of a bone-related cancer are bone cancer cells, neuroblastoma cells, osteosarcoma cells, Ewing sarcoma cells, chordoma cells, cells of a malignant fibrous histiocytoma of bone, prostate cancer cells, or cells of a fibrosarcoma of bone. 
     
     
         5 . The method of  claim 1 , wherein said cells of a bone-related cancer are not prostate cancer cells. 
     
     
         6 . The method of  claim 1 , wherein said placental cells are CD34 − , CD45 − , CD10 + , CD90 + , CD105 +  and CD200 + , as detectable by flow cytometry. 
     
     
         7 . The method of  claim 1 , wherein said placental cells are CD34 − , CD45 − , CD10 + , CD80 − , CD86 − , CD90 + , CD105 +  and CD200 + , as detectable by flow cytometry. 
     
     
         8 . The method of  claim 1 , wherein said contacting is performed in vitro. 
     
     
         9 . The method of  claim 1 , wherein said contacting is performed in vivo. 
     
     
         10 . The method of  claim 9 , wherein said contacting comprises administering said placental stem cells to a human individual comprising said cells of a bone related cancer. 
     
     
         11 . The method of  claim 10 , wherein said contacting comprises administering said placental stem cells to said individual at or adjacent to a bone lesion caused by said bone-related cancer. 
     
     
         12 . The method of  claim 10 , wherein said contacting comprises administering at least 1×10 8  of said placental stem cells to said individual. 
     
     
         13 . The method of  claim 1 , wherein said placental cells suppress proliferation of said cells of a bone-related cancer by at least 50% compared to proliferation of an equivalent number of cells of a bone-related cancer in the absence of said placental cells. 
     
     
         14 . A method of treating a human individual having a bone-related cancer, comprising administering to said individual a therapeutically effective amount of placental stem cells for a time sufficient for said placental stem cells to improve one or more symptoms of, or reduce the progression of, said bone-related cancer,
 wherein said placental stem cells are adherent to tissue culture plastic, are CD34 − , CD10 + , CD105 +  and CD200 +  as detectable by flow cytometry; are not trophoblasts, cytotrophoblasts or bone marrow-derived mesenchymal stem cells, and have the capacity to differentiate into osteogenic or chondrogenic cells.   
     
     
         15 . The method of  claim 14 , wherein said bone-related cancer is multiple myeloma. 
     
     
         16 . The method of  claim 14 , wherein said bone-related cancer is chondrosarcoma. 
     
     
         17 . The method of  claim 14 , wherein said bone-related cancer is bone cancer, neuroblastoma, osteosarcoma, Ewing sarcoma, chordoma, malignant fibrous histiocytoma of bone, prostate cancer, or fibrosarcoma of bone. 
     
     
         18 . The method of  claim 14 , wherein said cells of a bone-related cancer are not prostate cancer cells. 
     
     
         19 . The method of  claim 14 , wherein said placental stem cells are CD34 − , CD45 − , CD10 + , CD90 + , CD105 +  and CD200 + , as detectable by flow cytometry. 
     
     
         20 . The method of  claim 14 , wherein said placental stem cells are CD34 − , CD45 − , CD10 + , CD80 − , CD86 − , CD90 + , CD105 +  and CD200 + , as detectable by flow cytometry. 
     
     
         21 . The method of  claim 14 , wherein said placental stem cells are administered to said individual intravenously. 
     
     
         22 . The method of  claim 14 , wherein said placental stem cells are administered to said individual at or adjacent to a bone lesion caused by said bone-related cancer. 
     
     
         23 . The method of  claim 14 , comprising administering at least 1×10 8  placental cells to said individual. 
     
     
         24 . The method of  claim 14 , wherein said placental cells suppress proliferation of cells of said bone-related cancer by at least 50% compared to proliferation of an equivalent number of cells of said bone-related cancer in the absence of said placental cells.